Company* (Symbol)

Product

Description

Indication

Status (Date)

CANCER

British Biotech plc (UK; BBIOY) and BresaGen Ltd. (Australia; BSGNY; ASX:BGN)

E21R

Metalloenzyme inhibitor

Chronic myelomonocytic leukemia

BresaGen commenced patient recruitment for a Phase II study in Australia (3/6)

Canfite Ltd. (Israel)*

AFite

Oral antitumor drug for adjunctive treatment with chemotherapy

Cancer

Company began Phase I trials in Europe and the U.S. (3/6)

Millennium Pharmaceuticals Inc. (MLNM) and ILEX Oncology Inc. (ILXO)

Mab-Campath

Humanized monoclonal antibody; alemtuzumab

Chronic lymphocytic leukemia

Mab-Campath was recommended for approval in Europe under the condition the companies conduct a post-approval trial (3/30)

Pharmagenesis Inc.*

PG2

Plant-derived hematopoiesis enhancer that restores blood cells after destruction of bone marrow cells induced by chemotherapy

Cancer

Company said PG2 passed clinical trials in China (3/19)

PhotoCure ASA (Norway; OSE:PHO)

Metvix PDT

Photodynamic therapy; the cream is activated through illumination with a red light

High-risk basal cell carcinoma and actinic keratosis

Company submitted a marketing authorization application in Australia (3/15)

Ribozyme Pharmaceuticals Inc. (RZYM)

Herzyme

Ribozyme designed to downregulate the HER2/neu oncogene

Breast and ovarian cancer

Company submitted an IND to begin clinical trials in Canada (3/1)

CARDIOVASCULAR

Actelion Ltd. (Switzerland; SWX:ATLN)

Tracleer

Oral dual endothelin receptor antagonist, bosentan

Pulmonary arterial hypertension

Company filed for European Union marketing authorization (3/1)

Theratechnologies Inc. (Canada; TSE:TH)

ThGRF

Growth hormone-releasing factor analogue

Chronic obstructive pulmonary disease

Company began enrollment in a trial to assess safety and efficacy (3/6)

CENTRAL NERVOUS SYSTEM

Genmab A/S (Denmark; CSE:GEN)

HuMax-CD4

Fully human antibody

Rheumatoid arthritis

Phase I/II data indicate HuMax-CD4 was well tolerated, produced no serious adverse effects and no depletion of CD4-positive T cells (3/8)

INFECTION

Enzon Inc. (ENZN) and Schering-Plough Corp.

Peg-Intron

Peg-Intron injection and Rebetol capsules as a combination therapy

Chronic hepatitis C

European Commission granted marketing approval (3/28)

ID Biomedical Corp. (Canada; IDBE; TSE:IDB)

StreptAvax

A multivalent recombinant vaccine designed to protect against 26 serotypes

Group A stretococcus infection

Canadian authorities approved the start of a Phase I/II trial (3/22)

Immtech International Inc. (IMMT)

DB289

Oral, anti-infective

Pneumocystis carinii pneumonia and African sleeping sickness

Company completed a Phase I trial (3/7)

Interneuron Pharmaceuticals Inc. (IPIC)

PRO 2000

Vaginal microbicide

Sexually transmitted disease prevention

Company said PRO 2000 will be tested in a goverment-funded Phase II/III trial to begin later this year in Zimbabwe, Malawi, South Africa and India (3/1)

MISCELLANEOUS

Amgen Inc. (AMGN)

Aranesp

Darbepoetin alfa; an erythropoietic protein

Anemia

The European Committee on Proprietary Medicinal Products recommended approval (3/19)

Cellegy Pharmaceuticals Inc. (CLGY)

Rectogesic

Nitroglycerin ointment

Anal fissures

Company filed for marketing approval in South Korea (3/6)

Genzyme General (GENZ)

Fabrazyme

Agalsidase beta enzyme replacement therapy

Fabry disease

The Committee for Proprietary Medicinal Products issued a positive opinion on the marketing authorization application for Fabrazyme (3/28)

ICN Pharmaceuticals Inc. (NYSE:ICN)

Virazole

Intravenous ribavirin (100 mg/ml)

Hemorrhagicfever with renal syndrome

The European Commission granted orphan drug status designation (3/16)

QLT Inc. (Canada; QLTI) and Novartis Ophthalmics (unit of Novartis AG; Switzerland)

Visudyne (FDA-approved)

Verteporfin; a nonthermal laser light is shined into the patient's eye to activate the drug

Subfoveal choroidal neovascularization secondary to pathologic myopia

Visudyne received marketing approval in Europe for the new indication (3/23)

Trankaryotic Therapies Inc. (TKTX)

Replagal

Agalsidase alfa enzyme replacement therapy

Fabry disease

The Committee for Proprietary Medicinal Products issued a positive opinion on the marketing authorization application for Fabrazyme (3/28)

Vasogen Inc. (Canada; TSE:VAS; AMEX:MEW)

­

Immune modulation therapy

Moderate to severe psoriasis

Company received approval to proceed with a 105-patient trial in Canada (3/6)

Notes:

* Privately held.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange; OSE = Norwegian Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange

IND = Investigational New Drug application

No Comments